Abstract
In March 2009, everolimus (Afinitor; Novartis), an inhibitor of mTOR, was approved by the US FDA for the treatment of patients with advanced kidney cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Rapamycin golden jubilee and still the miraculous drug: a potent immunosuppressant, antitumor, rejuvenative agent, and potential contributor in COVID-19 treatment
Bioresources and Bioprocessing Open Access 13 June 2022
-
Predicting Radiation Resistance in Breast Cancer with Expression Status of Phosphorylated S6K1
Scientific Reports Open Access 20 January 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cohen, H. T. & McGovern, F. J. Renal-cell carcinoma. N. Engl. J. Med. 353, 2477–2490 (2005).
Garcia, J. A. & Rini, B. I. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J. Clin. 57, 112–125 (2007).
Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 1 Jun 2009 (doi: 10.1200/JCO.2008.20.1293).
Faivre, S., Kroemer, G. & Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nature Rev. Drug Discov. 5, 671–688 (2006).
Rini, B, Kar, S. & Kirkpatrick, P. Temsirolimus. Nature Rev. Drug Discov. 6, 599–600 (2007).
Schuler, W. et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64, 36–42 (1997).
Sedrani, R. et al. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc. 30, 2192–2194 (1998).
Food and Drug Administration. FDA labelling information. FDA web site [online], (2009).
Lane, H. A. et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin. Cancer Res. 15, 1612–1622 (2009).
Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449–456 (2008).
Atkins, M. B. et al. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer 115, S2247–S2251 (2009).
IMS MIDAS (2008).
Hauber, A. et al. JP Morgan European Equity Research Report (JP Morgan Chase and Company, 29 Jan 2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
M.B.A has received research support from Novartis and served on an advisory committee for Novartis.
Rights and permissions
About this article
Cite this article
Atkins, M., Yasothan, U. & Kirkpatrick, P. Everolimus. Nat Rev Drug Discov 8, 535–536 (2009). https://doi.org/10.1038/nrd2924
Issue Date:
DOI: https://doi.org/10.1038/nrd2924
This article is cited by
-
Rapamycin golden jubilee and still the miraculous drug: a potent immunosuppressant, antitumor, rejuvenative agent, and potential contributor in COVID-19 treatment
Bioresources and Bioprocessing (2022)
-
Redox balance and autophagy regulation in cancer progression and their therapeutic perspective
Medical Oncology (2022)
-
Predicting Radiation Resistance in Breast Cancer with Expression Status of Phosphorylated S6K1
Scientific Reports (2020)
-
Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro
Cancer Chemotherapy and Pharmacology (2018)
-
Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies
Apoptosis (2018)
